Cytoprotective doses of arbacet with minimal antisecretory properties are not effective in duodenal ulcer healing

Dov Wengrower, Alexander Fich, Eran Goldin, Rami Eliakim, Moshe Ligumsky, Daniel Rachmilewitz

Research output: Contribution to journalArticlepeer-review

Abstract

The efficacy of arbacet (a synthetic analog of prostaglandin E2) in definite cytoprotective but minimal antisecretory dose was evaluated in the treatment of duodenal ulcer. One hundred five patients with endoscopically proven duodenal ulcer were randomized in a double-blind manner to receive four times daily either arbacet 25 μg or placebo. Ulcer healing was assessed endoscopically after two and four weeks of treatment. The mean age, sex distribution, and tobacco and alcohol consumption were similar in the two treatment groups. The ulcers of 16 patients in both the placebo and the arbacet-treated group healed after 14 days of treatment. At the end of the study, healing of the ulcer was observed in 69.2% of the arbacet-treated patients and in 60.4% of patients in the placebo treated group. (Difference was not statistically significant). We conclude that cytoprotective doses of arbacet with minimal antisecretory properties are not effective in duodenal ulcer healing.

Original languageEnglish
Pages (from-to)857-860
Number of pages4
JournalDigestive Diseases and Sciences
Volume32
Issue number8
DOIs
StatePublished - Aug 1987
Externally publishedYes

Keywords

  • arbacet
  • duodenal ulcer
  • prostaglandins

Fingerprint

Dive into the research topics of 'Cytoprotective doses of arbacet with minimal antisecretory properties are not effective in duodenal ulcer healing'. Together they form a unique fingerprint.

Cite this